VIDEO: CheckMate 9ER's ‘negative biomarker discovery’ does not dampen continued exploration
Click Here to Manage Email Alerts
SAN FRANCISCO — In this video, Toni K. Choueiri, MD, highlights a biomarker analysis of CheckMate 9ER he presented at the annual ASCO Genitourinary Cancers Symposium.
In a post-hoc analysis, the researchers explored potential predicative biomarkers of efficacy for the nivolumab (Opdivo, Bristol Myers-Squibb)/cabozantinib (Cabometyx, Exelixis) combination treatment.
“Overall, we found that that select gene-expression signature that were previously found to be predictive in the PD-L1 plus VEGF combo — remember nivo/cabo is PD1 — these were not predictive of efficacy with PD1 and anti-VEGF targeted treatment,” Choueiri, Jerome and Nancy Kohlberg professor of medicine at Harvard Medical School and attending physician in solid tumor oncology, director of the Genitourinary Oncology Disease Center, and director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, said.
Despite this being a “negative biomarker discovery,” there is continuing effort to investigate other biomarkers, according to Choueiri.
Reference:
- Choueiri TK, et al. Abstract 608. Presented at: ASCO Genitourinary Cancers Symposium; Feb. 16-18, 2022; San Francisco.
Collapse
Healio Interviews
Click Here to Manage Email Alerts